African-American Hypertensive with CKD Study

  • admin
  • 30 Jul 2020
  •   Comments Off on African-American Hypertensive with CKD Study

African-Americans with Hypertensive CKD  overview

Chronic Kidney Disease (CKD), the progressive loss of kidney function, disproportionally impacts African-Americans, which are three to four times more likely to suffer from CKD than Caucasians. One of the most severe consequences of untreated CKD is an end-stage renal disease (ESRD), where the kidneys have ceased to function, and the individual requires continuous on-going dialysis or kidney transplantation.

Who takes part in the study?

Elixia Clinical Research is looking for African Americans patients who suffer from CKD, have high blood pressure and are non-diabetic located in South Florida, Tampa Bay Area or Philadelphia.

What are the benefits?

You will be paid for your time and participation in this study, $2,400 compensation plus the medication and transportation if they needed. Because of COVID-19, after the first visit the nurses goes to the patient’s house.

  • Increasing renal blood flow and filtration by dilating the renal arteries and reducing pressure;
  • Reducing inflammation, oxidative stress, and fibrosis;
  • Reducing kidney injury and levels of proteinuria; and
  • Restoration of the body’s ability to regulate sodium and potassium.

About the African Americans – Hypertensive with CKD

DM199 was created as a protein replacement therapy. In the case of non-diabetic, hypertensive African Americans with CKD, we believe that DM199 represents a potential shift in the treatment paradigm. We believe that DM199 may potentially act on the following inter-related mechanisms in the kidney to promote better overall function, stable blood flow, and ultimately may potentially protect the kidney from further damage.

What to expect

The study is designed to evaluate changes in eGFR (blood flow through the kidney) and protein albuminuria (renal filtration ability). Elixia Clinical Research also intends to identify subjects with the APOL1 risk allele(s) to assess its impact on response to DM199 therapy.

How to apply?

Send us an email to info@elixiacrc.com